Regional glucose metabolism due to the presence of cerebral amyloidopathy in older adults with depression and mild cognitive impairment

• Published in: Journal of affective disorders 2018-10, Vol.239, p.30-36
• Main Authors: Youn, HyunChul, Lee, Eun Seong, Lee, Suji, Suh, Sangil, Jeong, Hyun-Ghang, Eo, Jae Seon
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid; Amyloid - metabolism; Aniline Compounds - administration & dosage; Cerebral Cortex - diagnostic imaging; Cerebral Cortex - metabolism; Cognitive Dysfunction - diagnostic imaging; Cognitive Dysfunction - metabolism; Cross-Sectional Studies; Depression; Depressive Disorder - diagnostic imaging; Depressive Disorder - metabolism; FDG-PET; Female; Fluorodeoxyglucose F18 - administration & dosage; Glucose - metabolism; Humans; Hypometabolism; Male; Middle Aged; Mild cognitive impairment; Positron-Emission Tomography - methods; Radiopharmaceuticals - administration & dosage; Stilbenes - administration & dosage
• ISSN: 0165-0327; 1573-2517
• DOI: 10.1016/j.jad.2018.06.029

•Some depressed elders report cognitive decline in the prodromal Alzheimer's disease.•Depressed elders have different cerebral metabolism due to the cerebral amyloidopathy.•The results of 18F-FDG PET may predict cerebral amyloidopathy in depressed elders. Depression is a risk factor for mild cognitive impairment (MCI) and for the conversion from MCI to Alzheimer's disease (AD). This study investigated regional cerebral glucose metabolism (rCMglc) in older adults with depression and MCI, either with or without amyloidopathy. We recruited 31 older adults diagnosed with depression and MCI, and 21 older adults with normal cognition (NC). All participants completed demographic questionnaires and were examined with a standardized neuropsychological battery, F-18 fluorodeoxyglucose positron emission tomography (PET), and F-18 florbetaben PET. We classified subjects with depression and MCI into amyloid-β-positive (CDAP; n = 16) and amyloid-β-negative (CDAN; n = 15) groups. Pairwise rCMglc analyses were conducted between all three groups (CDAP vs. NC, CDAN vs. NC, and CDAP vs. CDAN). In comparison with the NC group, the CDAP group showed reduced rCMglc predominantly in temporoparietal regions, whereas the CDAN group showed lower rCMglc in regions of the frontal lobe, in addition to the temporoparietal regions. The CDAN group also showed lower rCMglc in right anterior cingulate and left inferior orbitofrontal regions, in a comparison between the CDAP and CDAN groups. The generalizability of the findings is limited because this study has a relatively small number of participants. In addition, this study used cross-sectional design rather than longitudinal design. Our findings may provide a reference to assess the risk of future cognitive deterioration. Consequently, this study is expected to contribute to prevention and early identification of dementia associated with AD.